Medicenna Therapeutics (TSX:MDNA) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

MDNA 주식 개요

면역 치료 기업인 메디세나 테라퓨틱스는 슈퍼카인의 개발 및 상용화를 통해 암 및 기타 질병 치료를 위한 슈퍼카인의 역량을 강화하는 데 주력하고 있습니다.

MDNA 기본 분석
눈송이 점수
가치 평가	0/6
미래 성장	5/6
과거 실적	0/6
재무 상태	6/6
배당금	0/6

보상

수익은 매년 57.2% 증가할 것으로 예상됩니다.

위험 분석

수익이 1백만 달러 미만인 경우 ( CA$0 )

지난 1년 동안 주주가 희석되었습니다.

Medicenna Therapeutics Corp. 경쟁사

Eupraxia Pharmaceuticals

TSX:EPRX

CA$129.3m

Oncolytics Biotech

TSX:ONC

CA$93.9m

Covalon Technologies

TSXV:COV

CA$93.2m

Satellos Bioscience

TSX:MSCL

CA$51.9m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Medicenna Therapeutics
과거 주가
현재 주가	CA$1.87
52주 최고치	CA$2.98
52주 최저치	CA$0.21
베타	1.26
11개월 변경	-9.66%
3개월 변경 사항	-7.43%
1년 변경 사항	367.50%
33년 변화	-45.95%
5년 변화	46.09%
IPO 이후 변화	-30.74%

최근 뉴스 및 업데이트

Recent updates

We Think Medicenna Therapeutics (TSE:MDNA) Needs To Drive Business Growth Carefully

Oct 18

Medicenna Therapeutics (TSE:MDNA) Is In A Good Position To Deliver On Growth Plans

Jun 14

Companies Like Medicenna Therapeutics (TSE:MDNA) Are In A Position To Invest In Growth

Feb 28

Here's Why We're Not Too Worried About Medicenna Therapeutics' (TSE:MDNA) Cash Burn Situation

Nov 08

Is Medicenna Therapeutics (TSE:MDNA) In A Good Position To Deliver On Growth Plans?

Mar 01

주주 수익률

	MDNA	CA Biotechs	CA 마켓
7D	-7.9%	-3.6%	0.5%
1Y	367.5%	-41.8%	20.9%

수익률 대 산업: MDNA 지난 1년 동안 -36.5 %를 반환한 Canadian Biotechs 산업을 초과했습니다.

수익률 대 시장: MDNA 지난 1년 동안 9.1 %를 반환한 Canadian 시장을 초과했습니다.

가격 변동성

Is MDNA's price volatile compared to industry and market?
MDNA volatility
MDNA Average Weekly Movement	9.6%
Biotechs Industry Average Movement	8.8%
Market Average Movement	8.3%
10% most volatile stocks in CA Market	17.2%
10% least volatile stocks in CA Market	3.0%

안정적인 주가: MDNA 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: MDNA 의 주간 변동성은 지난 1년 동안 17% 에서 12% 로 감소했습니다.

회사 소개

설립	직원	CEO	웹사이트
n/a	16	Fahar Merchant	www.medicenna.com

메디케나 테라퓨틱스는 면역치료제 개발 및 상용화를 통해 암 및 기타 질병 치료를 위한 슈퍼카인즈와 슈퍼카인즈에 힘을 실어주는 회사입니다. 이 회사는 재발성 교모세포종과 뇌종양 치료를 위한 인터루킨 4(IL-4) EC인 비작소퍼프(MDNA55)를 개발하고 있습니다. 또한 암과 싸우는 데 필요한 면역 세포를 활성화하고 증식시키는 IL-2의 강화 버전인 MDNA11, 다발성 경화증 및 이식편대숙주질환과 같은 자가 면역 질환을 위한 IL-2 길항제인 MDNA209, 암 면역 치료를 위한 이중 IL-4/IL-13 길항제인 MDNA413, 다양한 고형암을 위한 이중 기능 항 PD1-IL2 슈퍼카인인 MDNA113, 다양한 종양을 위한 IL-13 슈퍼카인인 MDNA132를 개발 중입니다.

Medicenna Therapeutics Corp. 기본 사항 요약

Medicenna Therapeutics 의 수익과 매출은 시가총액과 어떻게 비교하나요?
MDNA 기본 통계
시가총액	CA$144.64m
수익(TTM)	-CA$26.24m
수익(TTM)	n/a

0.0x

P/S 비율

-5.5x

P/E 비율

MDNA 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
MDNA 손익 계산서(TTM)
수익	CA$0
수익 비용	CA$0
총 이익	CA$0
기타 비용	CA$26.24m
수익	-CA$26.24m

최근 보고된 수익

Jun 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-0.34
총 마진	0.00%
순이익 마진	0.00%
부채/자본 비율	0%

MDNA 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

MDNA 주식 개요

보상

위험 분석

Medicenna Therapeutics Corp. 경쟁사

TSX:EPRX

CA$129.3m

TSX:ONC

CA$93.9m

TSXV:COV

CA$93.2m

TSX:MSCL

CA$51.9m

가격 내역 및 성능

최근 뉴스 및 업데이트

Medicenna Presents Preclinical Results from Its IL-2 Super-Antagonist and Anti -PD1-IL-2 Biskit Programs At the Promise of Interleukin-2 Therapy Conference

Medicenna Therapeutics Corp. Appoints Mr. Karim Lalji as New Addition to its Board of Directors

Medicenna Therapeutics Corp., Annual General Meeting, Sep 26, 2024

Medicenna Therapeutics Corp. Announces Ema Approval of Its Clinical Trial Application to Expand Its Phase 1/2 Ability-1 Study to Europe

Medicenna Therapeutics Presents Positive Survival Data for Bizaxofusp in Phase 2B Study At Asco 2024

Medicenna Therapeutics Files Form 15

Recent updates

Medicenna Presents Preclinical Results from Its IL-2 Super-Antagonist and Anti -PD1-IL-2 Biskit Programs At the Promise of Interleukin-2 Therapy Conference

Medicenna Therapeutics Corp. Appoints Mr. Karim Lalji as New Addition to its Board of Directors

Medicenna Therapeutics Corp., Annual General Meeting, Sep 26, 2024

Medicenna Therapeutics Corp. Announces Ema Approval of Its Clinical Trial Application to Expand Its Phase 1/2 Ability-1 Study to Europe

Medicenna Therapeutics Presents Positive Survival Data for Bizaxofusp in Phase 2B Study At Asco 2024

Medicenna Therapeutics Files Form 15

Medicenna Therapeutics Corp. announced that it has received CAD 20 million in funding from RA Capital Management, L.P.

Medicenna Therapeutics Corp. announced that it expects to receive CAD 20 million in funding from RA Capital Management, L.P.

Medicenna Therapeutics Corp. Presents Updated Results of Single Agent MDNA11 Anti-Tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study

Medicenna to Provide Clinical Update on the Mdna11 Ability-1 Trial At the Upcoming American Association for Cancer Research Annual Meeting

Medicenna Therapeutics Corp. Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with Keytruda® (Pembrolizumab) in Patients with Advanced Solid Tumors

Medicenna Therapeutics Corp. Announces Initiation of Enrollment in Combination Arm of Phase 1/2 ABILITY Study Evaluating MDNA11 with Merck’s Pembrolizumab

Medicenna Therapeutics Corp. Announces A Poster Presentation and an Oral Summary Highlighting Long-term Follow-up Up Results from the Phase 2b Clinical Trial of Bizaxofusp

Medicenna Therapeutics Corp. to Present 4 Year Follow-Up Phase 2B Bizaxofusp Survival Data in Recurrent Glioblastoma At the Society for Neuro-Oncology 2023 Annual Meeting

Medicenna Therapeutics Corp. Promising Single-Agent Response and Durability of MDNA11 in the Phase 1/2 ABILITY Study During Dose Escalation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer

Medicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated SuperKine (T-MASK) at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Medicenna Therapeutics Corp.(NasdaqCM:MDNA) dropped from NASDAQ Composite Index

Medicenna Therapeutics Corp. Announces the Departure of Jeff Caravella as Chief Financial Officer

New major risk - Revenue and earnings growth

Medicenna Therapeutics Corp. Announces Dosing of the First Patient in the Phase 2 Monotherapy Dose Expansion Portion of the Phase 1/2 ABILITY

We Think Medicenna Therapeutics (TSE:MDNA) Needs To Drive Business Growth Carefully

Medicenna Therapeutics Appoints Humphrey Gardner, as Chief Medical Officer

Medicenna Therapeutics Corp. Presents Preclinical MDNA223 BiSKIT Data at the AACR Special Conference on Tumor Immunology and Immunotherapy

Medicenna Therapeutics Corp. to Present at the AACR Special Conference Cancer Research: Tumor Immunology and Immunotherapy

Medicenna Therapeutics Corp. Announces the Appointment of Jeff Caravella as Chief Financial Officer

Medicenna Therapeutics Corp. Announces Departure of Elizabeth Williams as Chief Financial Officer

Medicenna Therapeutics Corp. Completes MDNA11 Dose Escalation and Commences Monotherapy Dose Expansion in the Phase 1/2 ABILITY Study

Medicenna Therapeutics Corp. Appoints Dr. Arash Yavari as Chair of Development Advisory Committee

Medicenna Therapeutics Corp., Annual General Meeting, Sep 28, 2023

New minor risk - Share price stability

Medicenna Therapeutics (TSE:MDNA) Is In A Good Position To Deliver On Growth Plans

Companies Like Medicenna Therapeutics (TSE:MDNA) Are In A Position To Invest In Growth

Medicenna Therapeutics Corp. to Report Q3, 2023 Results on Feb 07, 2023

Price target decreased to CA$7.00

High number of new and inexperienced directors

Medicenna Therapeutics Corp. Presents Updated Clinical Data from Dose Escalation Portion of Phase 1/2 Ability Study of Mdna11 At the Sitc Annual Meeting

Here's Why We're Not Too Worried About Medicenna Therapeutics' (TSE:MDNA) Cash Burn Situation

Price target increased to CA$12.00

Medicenna Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Lead Independent Director recently bought CA$74k worth of stock

Medicenna Therapeutics Corp. Confirms Partial Response in Pancreatic Cancer and Clinical Update on MDNA11’s Monotherapy Dose Escalation Portion of the Ongoing Phase 1/2 Ability Study

Medicenna Therapeutics Corp. Presents Preclinical Data Demonstrating Anti-Tumor Activity of Its Anti-Pd1-Il-2 Biskit and Long-Acting Il-4/Il-13 Super-Antagonist At Cytokines 2022

Medicenna Therapeutics Corp. Announces Clinical Collaboration with Merck to evaluate MDNA11 in combination with KEYTRUDA® (pembrolizumab) in ABILITY Trial

Medicenna Therapeutics Corp. has completed a Composite Units Offering in the amount of $20.000001 million.

Medicenna Therapeutics Corp. has completed a Composite Units Offering in the amount of $20.000001 million.

Medicenna Therapeutics Corp. to Report Q1, 2023 Results on Aug 15, 2022

Medicenna Announces New Clinical Data Providing Preliminary Evidence of MDNA11’s Single Agent Anti-Cancer Activity in the Phase 1/2 ABILITY Study

Medicenna Therapeutics Corp., Annual General Meeting, Sep 21, 2022

No longer forecast to breakeven

Price target decreased to CA$10.63

Medicenna Therapeutics Corp. to Report Fiscal Year 2022 Results on Jun 22, 2022

Medicenna Therapeutics Corp. to Report Fiscal Year 2022 Results on Jun 22, 2022

Medicenna Therapeutics Corp. Presents Phase 1/2 Ability Study Data Highlighting Mdna11's Favorable Clinical Profile At the 2022 Frontiers in Cancer Immunotherapy Meeting

Medicenna Therapeutics Corp. Announces New Clinical Data Showing Dose-Dependent Stimulation of Anti-Cancer Immune Cells with MDNA11 in the Phase 1/2 Ability Study

High number of new and inexperienced directors

Medicenna Announces Preclinical Data Highlighting the Potent Anti-Tumor Efficacy of Anti-PD1-IL-2 BiSKIT at the AACR Annual Meeting

Forecast to breakeven in 2025

Medicenna Therapeutics Corp. Announces Management Changes

Is Medicenna Therapeutics (TSE:MDNA) In A Good Position To Deliver On Growth Plans?